Immunoexpression of α2β1, α3β1, and α5β1 integrins in pleomorphic adenoma and adenoid cystic carcinoma. 2013

Márcia Cristina da C Miguel, and Joabe dos Santos Pereira, and Emanuel S de Souza Andrade, and Leão Pereira-Pinto, and Roseana de Almeida Freitas, and Lélia B de Souza
Department of Oral Pathology, Dentistry School, Federal University of Rio Grande do Norte, Rio Grande do Norte, Brazil.

The aim of the present study was to compare the expression of α2β1, α3β1, and α5β1 integrins between 28 pleomorphic adenomas (PAs) and 10 adenoid cystic carcinomas (ACCs), and investigate differences in the expression of these integrins according to histologic subtypes of ACCs. It was taken into consideration the presence or absence, distribution, and localization of integrin immunoexpression. There was immunoreactivity in the intercellular contacts of the strands, nests, and solid sheets of PAs, as well as in the luminal and nonluminal cells of the duct-like structures, with a predominant immunoexpression in the luminal cells. The immunoexpression in ACCs varied with histologic subtype of the tumor. It was verified for a tendency of absence and/or reduced expression of all integrins in the solid subtype of ACCs. In general, PAs revealed a more diffuse and remarkable immunoexpression of all studied integrins than ACCs. The reduced integrins expression in ACC may be related to a lesser degree of cell differentiation in this neoplasm. Moreover, the absence and/or reduced expression of the studied integrins in solid ACC suggest a possible role in pathogenesis and more aggressive biological behavior of this histologic subtype.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D008949 Adenoma, Pleomorphic A benign, slow-growing tumor, most commonly of the salivary gland, occurring as a small, painless, firm nodule, usually of the parotid gland, but also found in any major or accessory salivary gland anywhere in the oral cavity. It is most often seen in women in the fifth decade. Histologically, the tumor presents a variety of cells: cuboidal, columnar, and squamous cells, showing all forms of epithelial growth. (Dorland, 27th ed) Mixed Salivary Gland Tumor,Salivary Gland Tumor, Mixed,Syringoma, Chondroid,Adenomas, Pleomorphic,Chondroid Syringoma,Chondroid Syringomas,Pleomorphic Adenoma,Pleomorphic Adenomas,Syringomas, Chondroid
D003528 Carcinoma, Adenoid Cystic Carcinoma characterized by bands or cylinders of hyalinized or mucinous stroma separating or surrounded by nests or cords of small epithelial cells. When the cylinders occur within masses of epithelial cells, they give the tissue a perforated, sievelike, or cribriform appearance. Such tumors occur in the mammary glands, the mucous glands of the upper and lower respiratory tract, and the salivary glands. They are malignant but slow-growing, and tend to spread locally via the nerves. (Dorland, 27th ed) Cylindroma,Adenocystic Carcinoma,Adenocystic Carcinomas,Adenoid Cystic Carcinoma,Adenoid Cystic Carcinomas,Carcinoma, Adenocystic,Carcinomas, Adenocystic,Carcinomas, Adenoid Cystic,Cylindromas,Cystic Carcinoma, Adenoid,Cystic Carcinomas, Adenoid
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012468 Salivary Gland Neoplasms Tumors or cancer of the SALIVARY GLANDS. Cancer of Salivary Gland,Non-Sebaceous Lymphadenomas,Salivary Gland Cancer,Salivary Gland Lymphadenomas,Sebaceous Lymphadenomas,Cancer of the Salivary Gland,Neoplasms, Salivary Gland,Cancer, Salivary Gland,Cancers, Salivary Gland,Gland Neoplasm, Salivary,Gland Neoplasms, Salivary,Lymphadenoma, Non-Sebaceous,Lymphadenoma, Salivary Gland,Lymphadenoma, Sebaceous,Lymphadenomas, Non-Sebaceous,Lymphadenomas, Salivary Gland,Lymphadenomas, Sebaceous,Neoplasm, Salivary Gland,Non Sebaceous Lymphadenomas,Non-Sebaceous Lymphadenoma,Salivary Gland Cancers,Salivary Gland Lymphadenoma,Salivary Gland Neoplasm,Sebaceous Lymphadenoma
D014408 Biomarkers, Tumor Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or BODY FLUIDS. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including HORMONES; ANTIGENS; amino and NUCLEIC ACIDS; ENZYMES; POLYAMINES; and specific CELL MEMBRANE PROTEINS and LIPIDS. Biochemical Tumor Marker,Cancer Biomarker,Carcinogen Markers,Markers, Tumor,Metabolite Markers, Neoplasm,Tumor Biomarker,Tumor Marker,Tumor Markers, Biochemical,Tumor Markers, Biological,Biochemical Tumor Markers,Biological Tumor Marker,Biological Tumor Markers,Biomarkers, Cancer,Marker, Biochemical Tumor,Marker, Biologic Tumor,Marker, Biological Tumor,Marker, Neoplasm Metabolite,Marker, Tumor Metabolite,Markers, Biochemical Tumor,Markers, Biological Tumor,Markers, Neoplasm Metabolite,Markers, Tumor Metabolite,Metabolite Markers, Tumor,Neoplasm Metabolite Markers,Tumor Markers, Biologic,Tumor Metabolite Marker,Biologic Tumor Marker,Biologic Tumor Markers,Biomarker, Cancer,Biomarker, Tumor,Cancer Biomarkers,Marker, Tumor,Markers, Biologic Tumor,Markers, Carcinogen,Metabolite Marker, Neoplasm,Metabolite Marker, Tumor,Neoplasm Metabolite Marker,Tumor Biomarkers,Tumor Marker, Biochemical,Tumor Marker, Biologic,Tumor Marker, Biological,Tumor Markers,Tumor Metabolite Markers
D015870 Gene Expression The phenotypic manifestation of a gene or genes by the processes of GENETIC TRANSCRIPTION and GENETIC TRANSLATION. Expression, Gene,Expressions, Gene,Gene Expressions
D038982 Integrin alpha2beta1 An integrin found on fibroblasts, platelets, endothelial and epithelial cells, and lymphocytes where it functions as a receptor for COLLAGEN and LAMININ. Although originally referred to as the collagen receptor, it is one of several receptors for collagen. Ligand binding to integrin alpha2beta1 triggers a cascade of intracellular signaling, including activation of p38 MAP kinase. CD49b-CD29,Glycoprotein Ia-IIa,Platelet Membrane Glycoprotein Heterodimer Ia-IIa,VLA-2,Very Late Antigen-2,alpha2beta1Integrin,CD49b CD29,Glycoprotein Ia IIa,Late Antigen-2, Very,Platelet Membrane Glycoprotein Heterodimer Ia IIa,VLA 2,Very Late Antigen 2,alpha2beta1, Integrin
D039081 Integrin alpha5beta1 An integrin found in FIBROBLASTS; PLATELETS; MONOCYTES, and LYMPHOCYTES. Integrin alpha5beta1 is the classical receptor for FIBRONECTIN, but it also functions as a receptor for LAMININ and several other EXTRACELLULAR MATRIX PROTEINS. Receptors, VLA-5,Fibronectin Receptor,Integrin alpha-5 beta-1,Platelet Glycoprotein Ic-IIa,VLA-5,VLA-5 Receptors,Glycoprotein Ic-IIa, Platelet,Ic-IIa, Platelet Glycoprotein,Integrin alpha 5 beta 1,Platelet Glycoprotein Ic IIa,Receptor, Fibronectin,Receptors, VLA 5,VLA 5 Receptors,alpha-5 beta-1, Integrin,alpha5beta1, Integrin,beta-1, Integrin alpha-5
D039201 Integrin alpha3beta1 Cell surface receptor for LAMININ, epiligrin, FIBRONECTINS, entactin, and COLLAGEN. Integrin alpha3beta1 is the major integrin present in EPITHELIAL CELLS, where it plays a role in the assembly of BASEMENT MEMBRANE as well as in cell migration, and may regulate the functions of other integrins. Two alternatively spliced isoforms of the alpha subunit (INTEGRIN ALPHA3), are differentially expressed in different cell types. CD49c-CD29,Epiligrin Receptor,Galactoprotein b3,Gap b3,Integrin alpha(3)beta(1),Laminin-5 Receptor (alpha3beta1 integrin),VLA-3,alpha3beta1 Epiligrin Receptor,alpha3beta1 Integrin,Epiligrin Receptor, alpha3beta1,Integrin, alpha3beta1,Receptor, Epiligrin,Receptor, alpha3beta1 Epiligrin,alpha3beta1, Integrin

Related Publications

Márcia Cristina da C Miguel, and Joabe dos Santos Pereira, and Emanuel S de Souza Andrade, and Leão Pereira-Pinto, and Roseana de Almeida Freitas, and Lélia B de Souza
January 2024, Brazilian oral research,
Márcia Cristina da C Miguel, and Joabe dos Santos Pereira, and Emanuel S de Souza Andrade, and Leão Pereira-Pinto, and Roseana de Almeida Freitas, and Lélia B de Souza
June 1985, Histopathology,
Márcia Cristina da C Miguel, and Joabe dos Santos Pereira, and Emanuel S de Souza Andrade, and Leão Pereira-Pinto, and Roseana de Almeida Freitas, and Lélia B de Souza
December 2013, BMC cell biology,
Márcia Cristina da C Miguel, and Joabe dos Santos Pereira, and Emanuel S de Souza Andrade, and Leão Pereira-Pinto, and Roseana de Almeida Freitas, and Lélia B de Souza
June 2009, Head and neck pathology,
Márcia Cristina da C Miguel, and Joabe dos Santos Pereira, and Emanuel S de Souza Andrade, and Leão Pereira-Pinto, and Roseana de Almeida Freitas, and Lélia B de Souza
January 2018, Journal of cancer research and therapeutics,
Márcia Cristina da C Miguel, and Joabe dos Santos Pereira, and Emanuel S de Souza Andrade, and Leão Pereira-Pinto, and Roseana de Almeida Freitas, and Lélia B de Souza
January 2017, Archives of oral biology,
Márcia Cristina da C Miguel, and Joabe dos Santos Pereira, and Emanuel S de Souza Andrade, and Leão Pereira-Pinto, and Roseana de Almeida Freitas, and Lélia B de Souza
December 1990, Archives of pathology & laboratory medicine,
Márcia Cristina da C Miguel, and Joabe dos Santos Pereira, and Emanuel S de Souza Andrade, and Leão Pereira-Pinto, and Roseana de Almeida Freitas, and Lélia B de Souza
January 2011, Journal of cancer research and therapeutics,
Márcia Cristina da C Miguel, and Joabe dos Santos Pereira, and Emanuel S de Souza Andrade, and Leão Pereira-Pinto, and Roseana de Almeida Freitas, and Lélia B de Souza
July 2017, Pathology oncology research : POR,
Márcia Cristina da C Miguel, and Joabe dos Santos Pereira, and Emanuel S de Souza Andrade, and Leão Pereira-Pinto, and Roseana de Almeida Freitas, and Lélia B de Souza
January 2016, Turk patoloji dergisi,
Copied contents to your clipboard!